endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • a clinical trial
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

New TB drugs are safe, effective alternatives

Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.

 

13 July 2018

New interim findings from endTB indicate bedaquiline and delamanid could benefit many more patients.

Read more

O2 investigators meeting

endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris.

 

30 October 2018

endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris. Attendance and enthusiasm are high with participation from all countries currently active (Georgia, Kazakhstan, Lesotho, Peru, and South Africa) in the trial and from Pakistan, which is scheduled to begin randomization in early 2018. The meeting coincided with randomization of the 169th participant of a total of 750

PIH MSF MSF UNITAID